Dactinomycin
Cosmegen, Cubicin (dactinomycin) is a protein pharmaceutical. Dactinomycin was first approved as Cosmegen on 1982-01-01. It is used to treat choriocarcinoma, ewing sarcoma, gestational trophoblastic disease, kaposi sarcoma, and melanoma amongst others in the USA. It has been approved in Europe to treat bacteremia, bacterial endocarditis, bacterial skin diseases, gram-positive bacterial infections, and soft tissue infections.
| Trade Name | Cubicin |
|---|---|
| Common Name | Dactinomycin |
| Indication | bacteremia, bacterial endocarditis, bacterial skin diseases, choriocarcinoma, ewing sarcoma, gestational trophoblastic disease, gram-positive bacterial infections, kaposi sarcoma, melanoma, neuroblastoma, retinoblastoma, rhabdomyosarcoma, soft tissue infections, soft tissue neoplasms, testicular neoplasms, uterine neoplasms, wilms tumor |
| Drug Class | Antibiotics (Streptomyces strains) |
